TOI
BEARISH
$3.52
Live
The Oncology Institute, Inc. · NASDAQ
Target $7.0
(+98.9%)
$2.02
52W Range
$4.88
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 21, 2026
Market cap
$347.91M
P/E
N/A
ROE
N/A
Profit margin
-12.1%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
The Oncology Institute (TOI) exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price/Book ratio of -22.14, indicating negative shareholders' equity. While the company shows impressive top-line revenue growth of 41.60% YoY, it remains unprofitable with negative operating and profit margins. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual financial health and bearish insider selling patterns. The lack of a Graham Number or Altman Z-Score further underscores the company's distressed financial state.
Key Strengths
Strong YoY revenue growth of 41.60%
Robust Q/Q revenue growth of 41.58%
Healthy short-term liquidity with a Current Ratio of 1.59
Positive momentum in EPS growth (+68.4% YoY) despite remaining negative
Low Price-to-Sales ratio (0.69) suggesting potential undervaluation relative to revenue
Key Risks
Critical financial health (Piotroski F-Score 1/9)
Negative shareholders' equity as evidenced by Price/Book of -22.14
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
Bearish insider activity with multiple sales by Directors and the CFO
Negative profit and operating margins indicating an unsustainable cost structure
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
20
60
30
10
0
AI Verdict
High Risk / Speculative
Key drivers: Negative Equity, Piotroski Score 1/9, High Revenue Growth, Insider Selling
Confidence
90%
Value
20/100
P/E is N/A; stock is fundamentally 'unvaluable' by traditional defensive metrics.
Positives
- Low P/S ratio of 0.69
Watchpoints
- Negative Price/Book ratio
- No Graham Number available due to negative earnings/equity
Future
60/100
Growth is strong, but efficiency is lacking.
Positives
- Strong revenue growth trajectory
- Improving EPS growth percentages
Watchpoints
- Lack of a clear path to profitability
- Poor earnings surprise track record
Past
30/100
Historical volatility and long-term value destruction.
Positives
- Significant 3Y price recovery (+535.4%)
Watchpoints
- 5Y change is -65.3%
- History of massive earnings misses (e.g., -390.7% surprise in 2022)
Health
10/100
Altman Z-Score unavailable; Piotroski score indicates extreme weakness.
Positives
- Current Ratio > 1.5
Watchpoints
- Piotroski F-Score 1/9
- Negative ROA (-13.37%)
- Negative Equity
Dividend
0/100
Company is in a growth/distress phase; no capital return to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.52
Analyst Target
$7.0
Upside/Downside
+98.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TOI and closest competitors.
Updated 2026-04-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TOI
The Oncology Institute, Inc.
Primary
|
-65.3% | +535.4% | +47.3% | -17.0% | +6.0% | +6.7% |
|
TBRG
TruBridge, Inc.
Peer
|
-22.7% | -18.7% | -3.7% | +17.2% | +51.5% | +9.2% |
|
LAB
Standard BioTools Inc.
Peer
|
-80.7% | -51.6% | -19.1% | -30.5% | -8.2% | -2.2% |
|
KROS
Keros Therapeutics, Inc.
Peer
|
-80.9% | -70.2% | -8.5% | -28.6% | -0.6% | -6.6% |
|
SIGA
SIGA Technologies, Inc.
Peer
|
+2.3% | +19.3% | -0.8% | -35.2% | +10.7% | +9.2% |
TOI
The Oncology Institute, Inc.
Primary
5Y
-65.3%
3Y
+535.4%
1Y
+47.3%
6M
-17.0%
1M
+6.0%
1W
+6.7%
TBR
TruBridge, Inc.
Peer
5Y
-22.7%
3Y
-18.7%
1Y
-3.7%
6M
+17.2%
1M
+51.5%
1W
+9.2%
LAB
Standard BioTools Inc.
Peer
5Y
-80.7%
3Y
-51.6%
1Y
-19.1%
6M
-30.5%
1M
-8.2%
1W
-2.2%
KRO
Keros Therapeutics, Inc.
Peer
5Y
-80.9%
3Y
-70.2%
1Y
-8.5%
6M
-28.6%
1M
-0.6%
1W
-6.6%
SIG
SIGA Technologies, Inc.
Peer
5Y
+2.3%
3Y
+19.3%
1Y
-0.8%
6M
-35.2%
1M
+10.7%
1W
+9.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-22.0
PEG Ratio
N/A
P/B Ratio
-22.14
P/S Ratio
0.69
EV/Revenue
0.83
EV/EBITDA
-14.35
Market Cap
$347.91M
Profitability
Profit margins and return metrics
Profit Margin
-12.05%
Operating Margin
-4.87%
Gross Margin
15.2%
ROE
N/A
ROA
-13.37%
Growth
Revenue and earnings growth rates
Revenue Growth
+41.6%
Earnings Growth
N/A
Q/Q Revenue Growth
+41.58%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.59
Good
Quick Ratio
1.31
Good
Cash/Share
$0.34
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
16.0%
Op. Margin
-4.9%
Net Margin
-5.3%
Total Assets
$0.2B
Liabilities
$0.2B
Equity
$-0.0B
Debt/Equity
-11.47x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
67%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-03-12
$-0.06
+33.3% surprise
2025-11-13
$-0.14
-23.5% surprise
2025-08-13
$-0.15
-25.0% surprise
Healthcare Sector Comparison
Comparing TOI against 498 companies in the Healthcare sector
(28 bullish, 153 neutral, 317 bearish)
Profit Margin
-12.05%
This Stock
vs
-15.87%
Sector Avg
-24.0%
(Weaker)
Revenue Growth
41.6%
This Stock
vs
137.48%
Sector Avg
-69.7%
(Slower)
Current Ratio
1.59
This Stock
vs
4.66
Sector Avg
-65.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TOI
The Oncology Institute, Inc.
|
BEARISH | $347.91M | - | -% | -12.1% | $3.52 | |
|
TBRG
TruBridge, Inc.
|
NEUTRAL | $347.91M | 79.93 | 2.5% | 1.3% | $23.18 | Compare |
|
LAB
Standard BioTools Inc.
|
BEARISH | $345.33M | - | -13.1% | -87.8% | $0.89 | Compare |
|
KROS
Keros Therapeutics, Inc.
|
NEUTRAL | $341.37M | 4.87 | 19.9% | 35.7% | $11.21 | Compare |
|
SIGA
SIGA Technologies, Inc.
|
BEARISH | $341.03M | 14.88 | 11.2% | 24.6% | $4.76 | Compare |
TOI
The Oncology...
BEARISH
Mkt Cap
$348M
P/E
-
ROE
-%
Price
$3.52
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-16 | KAUSHAL MOHIT | Director | Sale | 95,719 | $335,133 |
| 2026-04-09 | CHERNETT JOREY | Beneficial Owner of more than 10% of a Class of Security | Purchase | 20,000 | $62,000 |
| 2026-03-27 | VIRNICH DANIEL | Chief Executive Officer | Stock Award | 670,608 | - |
| 2026-03-27 | PODNOS YALE | Officer | Stock Award | 66,446 | - |
| 2026-03-27 | CARTER ROBERT ROSS | Chief Financial Officer | Stock Award | 202,914 | - |
| 2026-03-27 | LANGSAM JEFFREY | Officer | Stock Award | 70,270 | - |
| 2026-03-27 | ENGLAND KRISTIN | Officer | Stock Award | 55,743 | - |
| 2026-03-27 | CHERNETT JOREY | Beneficial Owner of more than 10% of a Class of Security | Purchase | 27,429 | $81,190 |
| 2026-03-26 | CHERNETT JOREY | Beneficial Owner of more than 10% of a Class of Security | Purchase | 50,000 | $157,500 |
| 2026-03-24 | CHERNETT JOREY | Beneficial Owner of more than 10% of a Class of Security | Purchase | 125,000 | $388,750 |
| 2026-03-20 | CHERNETT JOREY | Beneficial Owner of more than 10% of a Class of Security | Purchase | 25,000 | $83,750 |
| 2026-03-17 | CHERNETT JOREY | Beneficial Owner of more than 10% of a Class of Security | Purchase | 398,985 | $1,225,101 |
| 2026-01-02 | CARTER ROBERT ROSS | Chief Financial Officer | Sale | 247 | $879 |
| 2025-12-15 | HIVELY BRADFORD DANIEL | Director | Sale | 13,333 | $50,291 |
| 2025-11-20 | PACALA MARK L. | Director | Stock Award | 81,790 | - |
KAUSHAL MOHIT
Director
2026-04-16
95,719 shares
·
$335,133
CHERNETT JOREY
Beneficial Owner of more than 10% of a Class of Security
2026-04-09
20,000 shares
·
$62,000
VIRNICH DANIEL
Chief Executive Officer
2026-03-27
670,608 shares
PODNOS YALE
Officer
2026-03-27
66,446 shares
CARTER ROBERT ROSS
Chief Financial Officer
2026-03-27
202,914 shares
LANGSAM JEFFREY
Officer
2026-03-27
70,270 shares
ENGLAND KRISTIN
Officer
2026-03-27
55,743 shares
CHERNETT JOREY
Beneficial Owner of more than 10% of a Class of Security
2026-03-27
27,429 shares
·
$81,190
CHERNETT JOREY
Beneficial Owner of more than 10% of a Class of Security
2026-03-26
50,000 shares
·
$157,500
CHERNETT JOREY
Beneficial Owner of more than 10% of a Class of Security
2026-03-24
125,000 shares
·
$388,750
CHERNETT JOREY
Beneficial Owner of more than 10% of a Class of Security
2026-03-20
25,000 shares
·
$83,750
CHERNETT JOREY
Beneficial Owner of more than 10% of a Class of Security
2026-03-17
398,985 shares
·
$1,225,101
CARTER ROBERT ROSS
Chief Financial Officer
2026-01-02
247 shares
·
$879
HIVELY BRADFORD DANIEL
Director
2025-12-15
13,333 shares
·
$50,291
PACALA MARK L.
Director
2025-11-20
81,790 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
B. Riley Securities
2026-03-13
Buy
Buy
Needham
2026-03-13
Buy
Buy
Needham
2026-03-09
Buy
Buy
BTIG
2026-03-09
Buy
Buy
Needham
2025-11-25
Buy
Past News Coverage
Recent headlines mentioning TOI from our newsroom.
Newest → oldest
No matching news yet.